Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Baltics has been experiencing steady growth in recent years, driven by several factors.
Customer preferences: Patients in Baltics are increasingly seeking out more effective and targeted treatments for rheumatic diseases, such as rheumatoid arthritis and lupus. This has led to a growing demand for biologic drugs, which are designed to specifically target the underlying causes of these diseases. Additionally, patients are increasingly seeking out more convenient and less invasive treatment options, such as self-administered injectable drugs.
Trends in the market: One major trend in the Anti-Rheumatic Drugs market in Baltics is the increasing use of biosimilars, which are lower-cost versions of biologic drugs. This has been driven in part by the growing availability of biosimilars in the region, as well as by efforts to reduce healthcare costs. Another trend is the growing use of combination therapies, which involve the use of multiple drugs to treat rheumatic diseases. This approach has been shown to be more effective than using a single drug alone.
Local special circumstances: One unique factor impacting the Anti-Rheumatic Drugs market in Baltics is the relatively low prevalence of rheumatic diseases in the region. This has led to a smaller market size compared to other regions, but also presents opportunities for growth as awareness of these diseases increases and more patients seek out treatment. Additionally, the region's healthcare systems are generally well-developed and provide good access to healthcare services, which has helped to support the growth of the Anti-Rheumatic Drugs market.
Underlying macroeconomic factors: The overall economic environment in Baltics has been relatively stable in recent years, which has helped to support growth in the Anti-Rheumatic Drugs market. Additionally, the region's aging population is driving demand for treatments for rheumatic diseases, as these conditions are more common among older adults. However, the region's relatively small market size and the presence of low-cost competitors could pose challenges for companies looking to enter or expand in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
